Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ICON, Lilly Extend Data Management Pact To Japan | Contract Pharma

What are you searching for?

Sign in
Breaking News

ICON, Lilly Extend Data Management Pact To Japan

ICON has signed an extension to its strategic agreement with Lilly to manage the company’s clinical data outside the U.S. ICON will now also oversee Lilly’s needs in Japan in addition to those in Europe, Canada, Latin America, Australia and As

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ICON has signed an extension to its strategic agreement with Lilly to manage the company’s clinical data outside the U.S. ICON will now also oversee Lilly’s needs in Japan in addition to those in Europe, Canada, Latin America, Australia and Asia.

“Today’s announcement is a continuation of a very successful partnership between ICON and Lilly,” commented Peter Gray, chief executive officer at ICON. “Through our existing data management partnership, we have brought significant process efficiencies to Lilly in helping them progress their drug development pipeline. That Lilly has chosen ICON to manage this important business function in such a key region as Japan is a measure of our global data management expertise and our local capabilities in the region.”

“With this transaction, Lilly Data Sciences and Solutions realizes its objective to leverage external, scalable clinical data management capabilities around the globe,” said Jeff Kasher, Lilly’s vice president and chief operating officer of Global Clinical Development. “We’re pleased to extend our relationship with ICON to include Japan, and their proven ability to reliably deliver work within differing cultural climates provided Lilly the opportunity to take another significant step in our ongoing agenda to increase flexibility, reduce fixed cost, and focus internal resources on core capabilities.”


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics